# About Sermorelin Legit: An Independent Editorial Digest of the GHRH(1-29) Record

> Sermorelin Legit is an independent editorial project that publishes cited summaries of the peer-reviewed sermorelin research. Not a clinic, not a vendor — a status console for the GHRH(1-29) record.

An independent editorial reading of the sermorelin literature, built as a status console: every regulatory and research fact carried back to its source.

## What this site is

Sermorelin Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The design borrows the grammar of an operations console on purpose: every regulatory and evidentiary fact is presented as a verifiable status with a provenance string, rather than as a marketing assertion. When the record says a finding belongs to the related analog tesamorelin, we mark it as tesamorelin. When the long-term adult data are thin, we leave that gap visible rather than papering over it.

## Why "legit"

The word "legit" in the domain name is editorial framing, not a legal or quality claim about any seller. The "legit" question people bring to sermorelin is really a due-diligence question: is it real, was it ever FDA-approved, what is its current standing? Those are answerable from the public record, and that is what this site does — it reads the regulatory and research facts straight.

What we can verify, we state with its source: sermorelin was FDA-approved as a prescription GHRH analog (NDA 020443) for pediatric growth hormone deficiency, was withdrawn from the US market in 2008 for commercial reasons, and is now compounded under FDA's interim Category 1 Section 503A policy. We do not make claims about the legitimacy of any particular vendor, and the modifier is a position this publisher occupies relative to the literature, not a statement about the site's services.

## How we handle the evidence

Every quantitative claim on this site maps to a numbered citation with a PMID or DOI. We separate what the published evidence establishes (the pediatric height-velocity acceleration, the older-men GH/IGF-1 reversal) from what is mechanistically plausible but unproven (general adult muscle-building, weight loss), and from hypothesis-generating frontier signals (cardiac-repair and in-silico glioma findings). We describe research findings only; we do not recommend doses for human use, and we name no product brands.

---

A status-console reading of the sermorelin record — every regulatory and GH/IGF-1 fact tagged with its source and its operational state, the formerly-approved-now-compounded standing reported as filed and the thin adult anti-aging evidence flagged in plain view; no clinic behind this console and nothing here dosed, dispensed, or sold.